AUTHORS
Amir Mahmoud, MBBCh, MSc, Shreya Srivastava, MD, MBA2, Pavania Elavalakanar, MSc, BSc3, Joseph B. An4, Ahmad Hassan5, Alexander Nelson6, Eleni Papachristodoulou7, Giovanna Giordano8, Olivia Min9, Sana Rehman10, Anjlee Mahajan, MD11, Kristen Marie Sanfilippo, MD, MPHS12, Shruti Chaturvedi Jr, MBBS, MS13, Rushad Patell, MD14
AFFILIATIONS
1 Washington University in St. Louis, St. Louis, Missouri, United States
2 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
3 University of New England, Biddeford, ME, United States
4 University of California, Davis, Sacramento, California, United States
5 Washington University in St. Louis, St. Louis, Missouri, United States
6 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
7 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
8 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
9 Washington University in St. Louis, St. Louis, Missouri, United States
10 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
11 University of California, Davis, Sacramento, California, United States
12 Washington University in St. Louis, St. Louis, Missouri, United States
13 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
14 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Background: Triple-positive antiphospholipid syndrome (APS) is associated with an elevated risk of recurrent thrombosis, and long-term anticoagulation with a vitamin K antagonist is recommended. In contrast, the clinical phenotype, thrombotic risk, and optimal antithrombotic management of patients with single- or double-positive antiphospholipid antibody (aPL) profiles remain uncertain. We evaluated APS manifestations, thrombotic burden, treatment patterns, and recurrent thrombosis in patients with non-triple-positive APS.
Methods: We conducted a multicenter retrospective cohort study of adults with single- or double-positive APS at four US academic centers. APS was defined by revised Sapporo criteria; triple-positive APS was excluded. Demographics, aPL profiles, APS manifestations, thrombotic and obstetric histories, and antithrombotic therapy were manually abstracted using harmonized instruments. Thrombotic events were classified as venous thromboembolism (VTE), arterial thromboembolism (ATE), or other thrombosis and characterized by site, provoking factors, and high-risk VTE or cardiovascular features based on 2023 ACR/EULAR criteria. Anticoagulant exposure, including treatment dates and transitions, was assessed longitudinally. The primary outcome was recurrent thrombosis during longitudinal follow-up.
Results: We included 462 patients followed for 2374.9 patient-years [median, 4.6 years (IQR, 2.6–6.6)]; 343 (74.2%) were single-positive and 119 (25.8%) double-positive. The median age at APS diagnosis was 48 years (IQR, 37–59), 72.9% were female, 63.6% self-identified as White, 23.8% as Black, and 12.6% another or mixed race. Thrombotic APS was present in 371 patients (80.3%), while 56.5% (148/262) of ever-pregnant patients had obstetric complications. Other manifestations included thrombocytopenia (17.1%), cardiac valve thickening or vegetation (6.5%), and catastrophic APS (1.7%).
Among patients with thrombotic APS, the median number of events was 1 (IQR, 1–2). The 541 events comprised 381 VTE, 154 ATE, and 6 other events (2 arteriovenous fistula thromboses, 2 renal thrombotic microangiopathy events, 1 lupus vasculitis-associated thrombosis, and 1 ischemic bowel event). VTE included deep vein thrombosis (60.3%), pulmonary embolism (27.2%), retinal vein occlusion (2.4%), and other or unknown sites (11.5%); 22.9% were provoked and 17.8% met high-risk VTE criteria. ATE included stroke (76%), myocardial infarction (11%), peripheral arterial disease (4.5%), and other sites (8.4%); 11.7% occurred in patients with a high-risk cardiovascular profile.
Most patients with thrombotic APS (96.1%) initiated antithrombotic therapy: warfarin in 55.8%, a direct oral anticoagulant (DOAC) in 24.7% (55 rivaroxaban, 36 apixaban, 1 dabigatran), enoxaparin in 9.4%, aspirin alone in 5.9%, and fondaparinux in 0.3%. Among 92 DOAC initiators, 45 (48.9%) switched agents: 32 to warfarin, 8 to another DOAC, 3 to enoxaparin or fondaparinux, and 2 to aspirin. Among 207 warfarin initiators, 45 (21.7%) switched: 38 to a DOAC, 6 to enoxaparin or fondaparinux, and 1 to aspirin. At follow-up end, 69.0% remained anticoagulated: 46.6% with warfarin, 16.9% a DOAC, 3.8% enoxaparin, and 1.6% fondaparinux, with or without antiplatelet therapy. The remaining 31.0% (115/371) were not anticoagulated; 102 had discontinued after a median 15 months (IQR, 3–44).
Recurrent thrombosis occurred in 42.5%. Recurrence was lower with initial DOAC than warfarin therapy (33.7% vs 49.8%; P=0.009), although the median event number did not differ. Event burden was highest among patients ultimately switched to enoxaparin (median, 2.5; IQR, 1–5) or fondaparinux (3.5; IQR, 2–5), versus warfarin, a DOAC, or no anticoagulation (1; IQR, 1–2; P<0.01), likely reflecting treatment selection for refractory disease.
Conclusions: In this multicenter US cohort, single- and double-positive APS demonstrated heterogeneous thrombotic phenotypes. Although recurrent thrombosis was common, the overall thrombotic burden was low for most patients and was concentrated in a smaller subgroup with multiple events and frequent treatment escalation. Comparisons according to initial anticoagulant choice may have been influenced by treatment selection and subsequent switching. These findings highlight the need to better define which patients with non-triple-positive APS require prolonged or intensified anticoagulation and which may be candidates for more individualized treatment strategies.
DISCLOSURES
Amir Mahmoud, MBBCh, MSc: No relevant conflicts of interest to declare.